The T‑SPOT®.PRT (Panel of Reactive T cells) test is available in the United States* as a laboratory developed test (LDT) for the PROTECT and REACT clinical trials. The T‑SPOT.PRT test assesses a solid organ transplant candidate’s T cell response to foreign tissue, referred to as alloreactivity.

In transplant, understanding the likelihood of a rejection event is an important factor in patient management. A T cell immune response to the donated organ can lead to T cell mediated rejection (TCMR), which is a complication detrimental to the survival of the organ. The T‑SPOT.PRT test measures a transplant candidate’s T cell mediated response to cells representing the potential donor population. This test may help clinicians identify patients at increased risk of TCMR, which in turn may guide decisions regarding immunosuppressive therapies. Studies are underway to assess the relationship of pre-transplant T‑SPOT.PRT test response to post-transplant outcomes.

The T‑SPOT.PRT test leverages Oxford Immunotec’s proprietary T‑SPOT technology. The test will be performed at Oxford Diagnostic Laboratories in Memphis, TN.

For more information please email PRTinfo@oxfordimmunotec.com.

*The T‑SPOT.PRT test is available as a laboratory developed test in the USA offered by Oxford Diagnostic Laboratories®. Oxford Diagnostic Laboratories is Clinical Laboratory Improvement Amendments (CLIA)-certified and College of American Pathologists (CAP) accredited to perform high complexity clinical laboratory testing. This test has not been approved or cleared by the FDA. The T‑SPOT.PRT test is pending approval in California, New York and Florida.

T‑SPOT and the Oxford Diagnostic Laboratories are registered trademarks of Oxford Immunotec Ltd.